Due to the development of gene detection and molecular subtype classification, endocrine therapy have formed for BC patients who expresses estrogen receptors (ER) and/or progesterone receptors (PR), while targeted therapy have used for patients with human epidermal growth factor receptor 2 (HER2) amplification [3]. Here, PGR is linked to breast cancer.